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ABSTRACT
Graft-versus-host disease (GVHD) remains a frequent and severe complication of allogeneic stem cell trans-
plantation (SCT). One approach to reducing alloreactivity is to deplete the graft of alloreactive T cells. Global
T cell depletion results in poor immune reconstitution with high mortality from viral infections and disease re-
lapse. Therefore, an approach to selectively deplete alloreactive T cells without compromising other responses
would be highly beneficial. We undertook studies to identify an inducible activation marker expressed on allor-
eactive effector T cells following culture with HLA-mismatched allostimulators. Compared to other markers,
CD134 was superior because of its negative baseline expression and rapid upregulation after activation. Deple-
tion of CD1341 cells from responder populations dramatically reduced specific alloreactivity as determined by
reduction of helper T cell precursor frequencies below the threshold predicting development of clinical GVHD
while retaining responses to third-party alloantigens. CD134-allodepleted populations retained effectors spe-
cific for the Wilms’ tumor (WT1) leukemia antigen as determined by WT1 specific pentamers, and CMV-
specific effectors as determined by CMV-specific pentamers and CMV-specific ELISpot. Thus, use of
CD134-allodepleted grafts may improve allogeneic SCT by reducing GVHD without loss of pathogen-specific
and leukemia-specific immunity.
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Graft-versus-host disease (GVHD) remains a fre-
quent and severe complication of allogeneic stem cell
transplantation (SCT). Recognition of recipient allo-
antigens by donor T cells forms the basis of GVHD
[1,2]. Numerous interventions have been employed
against GVHD, most of which target the number
and the function of T cells transferred from the donor
to the recipient. Nonspecific inhibitors of T cell acti-
vation including cyclosporine A or tacrolimus are ad-
ministered routinely to all SCT recipients [3-5].
Additional strategies target the T cells within the
transferred graft, either by negative depletion of
CD31 T cells or by transfer of positively selected
CD341 stem cells [6-8]. In other cases, polyclonal or
monoclonal antibodies have been used to purge the518allograft, or can be administered to the recipient
around the time of graft infusion, including antithy-
mocyte globulin or Campath-1H [9,10]. Although
these strategies reduce the risk of GVHD, the benefits
are often offset by the simultaneous nonspecific reduc-
tion of nonalloreactive T cell function, leading to pro-
longed posttransplantation immunodeficiency and to
increased risk of infection and disease relapse [11,12].
Thus, practical methods to allow specific depletion
of alloreactive T cells while sparing other T cell pop-
ulations, thereby preserving graft-versus-leukemia
(GVL) and pathogen-specific immune responses could
have clinical use in the setting of SCT.
Twomajor approaches have evolved to address this
problem: induction of anergy, and specific depletion of
alloreactive T cells responsible for GVHD, known as
Selective Allodepletion by Targeting CD1341 T Cells 519selective allodepletion. Induction of anergy in donor
alloreactive T cells can be achieved by ex vivo culture
of donor T cells with host peripheral blood mononu-
clear cells in the presence of costimulatory blockade
[13-16]. However, a major concern is that anergized
cells may have an inhibitory effect on bystander T
cells, or that their anergic state can be reversed in the
context of high levels of IL-2 or other common gamma
chain signaling cytokines [17-19]. Selective allodeple-
tion has the advantage that alloreactive T cells are
permanently eliminated. In mouse models, in vivo
allodepletion can be induced with CD25, CD69, or
CD95-specific antibodies [20-22]. In human systems,
selective allodepletion can be achieved by elimination
of donor T cells that have been activated after ex
vivo coculture with recipient antigen-presenting cells
(APC). After culture with recipient allogeneic stimula-
tor cells, activated donor T cells express a number of
activation markers including CD25, CD69, CD71,
and HLA-DR. Depletion of alloreactive T cells using
a cocktail of relevant antibodies resulted in a 10-fold
reduction in the alloantigen-specific helper T cell pre-
cursor (HTLp) frequency without significant reduc-
tion in third-party reactive HTLp [23-26]. Clinical
studies have been performed using CD25-based selec-
tive allodepletion after incubation with haploidentical
and matched sibling PBMC ex vivo [26,27]. Although
this approach is promising, posttransplant infections,
disease relapse, and residualGVHD remain a problem.
As our knowledge about the identification and func-
tion of regulatory T cells (Treg) is increasing, it also
becomes apparent that depletion of CD251 T cells
will result in loss of Treg from the graft. Thus, an al-
loantigen-primed T cell inoculum deprived of Treg
may induce GVHD even after allodepletion, because
of the loss of the natural suppressive function of
Treg. These observations mandate further experimen-
tation to improve our strategies for allodepletion.
Costimulatory molecules play a major role in acti-
vation of the effector T cells involved in GVHD. Be-
sides CD28, which has been extensively studied as
the paradigm of costimulatory function, costimulatory
molecules of the TNF receptor (TNFR) superfamily
have a critical role in regulating both acute and chronic
GVHD (aGVHD, cGVHD) [28-31]. Whereas certain
TNFR family molecules including Fas, TNFRI, and
TRAILR are involved in inducing apoptosis, others
such as CD40L, CD27, CD30, CD134 (OX40),
CD137 (4-1BB), and GITR are thought to enhance
T cell activation and survival [32,33]. These TNFR
family members signal through common TNFR-asso-
ciated factors, activate PI3K–Akt–NF-kB pathways
[34,35] and upregulate expression of Bcl-2 family
members and survivin [34,36-38]. In contrast to
CD28, which is constitutively expressed, members of
the TNFR superfamily are induced upon T cell activa-
tion [32,33] and therefore their expression can also beused as an indicator of T cell activation status during
GVHD [28].
CD134 is expressed on activated CD41 and CD81
T cells [30,39]. The interaction of CD134 with its
ligand (OX40L), a TNF family molecule, generates
costimulatory signals, resulting in enhanced T cell
proliferation and cytokine production. OX40 ligation
is known to be crucial for appropriate antigen presen-
tation by dendritic cells leading to clonal expansion
and long-term survival of antigen-specific T cells
[40]. In murine models, CD134 (OX40):OX40L inter-
actions play an important role in the pathogenesis of
GvHD [41]. In contrast, administration of a blocking
anti-CD134L monoclonal antibody successfully ame-
liorated lethal aGVHD in mice after bone marrow
transplantation with induction of hyporesponsiveness
to host alloantigens [42]. Importantly, preclinical stud-
ies have shown that expression of CD134 on peripheral
CD41 and CD81 cells strongly correlates with
aGVHD and cGVHD in patients undergoing alloge-
neic SCT [28,29,31].
In the present study we evaluated the potential role
of CD134 as a target for selective allodepletion. Our
studies showed that expression of CD134 is induced
on alloreactive human T cells early during their cul-
ture with allogeneic stimulators. Depleting CD1341
alloreactive T cells resulted in a T cell population
that had reduced alloantigen-specific reactivity as de-
termined by reduction of helper T cell precursor
frequencies to levels lower than those predictive for
clinical GVHD. Detailed analysis revealed that, by
this approach, functional CMV-specific effectors
were retained as determined by their identification
with CMV-specific pentamers and assessment of their
functional responses by CMV-specific ELISpot. Ef-
fectors for Wilms’ tumor (WT1) leukemia antigen
and third-party allostimulators were also retained. In
addition, depletion of CD1341 alloreactive T cells
preserved Foxp31Treg cells in the allodepleted popu-
lations. These observations suggest that use of
CD134-depleted allografts may improve allogeneic
SCT by reducing GVHD without loss of pathogen-
specific and leukemia-specific immunity.
MATERIALS AND METHODS
Cell Preparations and Primary Mixed Lymphocyte
Reaction (MLR)
PBMC were prepared from leukopacks (platelet
apheresis byproduct) obtained from Massachusetts
General Hospital and Children’s Hospital Boston.
A protocol for collection of this material has been
approved by the Institute’s institutional review board.
Mononuclear cells were isolated by Ficoll (Amersham-
Pharmacia Biotech, Piscataway, NJ) gradient centrifu-
gation. Monocyte-derived dendritic cells (DC) were
generated from PBMC according to previously
520 X. Ge et al.established protocol [43]. Briefly CD141 monocytes
were isolated by negative selection using Monocyte
Isolation Kit II from Miltenyi Biotec (Auburn, CA),
cultured in X-VIVO 20 medium (Cambrex Bio Sci-
ence Walkersville, Inc., Walkersville, MD) containing
1% heat-inactivated fetal calf serum (FCS), and sup-
plemented on days 0, 2, and 4 with 25 ng/mL IL-4 (Bi-
osource International, Camarillo, CA) and 25 ng/mL
GM-CSF (BD PharMingen, San Diego, CA). DC
maturation was accomplished on days 6 through 8 by
culture with IL-4 (25 ng/mL) and GM-CSF (25 ng/
mL) supplemented with IL-1b (10 ng/mL; US Biolog-
ical, Swampscott, MA), TNF-a (10 ng/mL; BD Phar-
Mingen), IL-6 (1000 U/mL; BD PharMingen), and
PGE2 (1 mg/mL; Sigma-Aldrich, St. Louis, MO). Ma-
ture DC were consistently CD11c1, CD401, CD831,
CD801, CD861, HLA ABC1, HLA-DR1, CD32 and
CD142 (Supplement Figure 2 and 3). For primary
MLR, irradiated (3300 cGy) stimulator DCs were cul-
tured at 1:20 ratio with responder PBMC in complete
culture medium for various time intervals.
Depletion of CD1341 Alloreactive T Cells and
Secondary MLR
After 2 days of coculture with stimulator DC, re-
sponder PBMC were stained with anti-CD134-PE
(clone ACT35; BD PharMingen) and anti-CD11c-
PE mAb (BD PharMingen; to identify and remove
stimulator DC). The cells were subsequently incu-
bated with anti-PE microbeads and passed through
an LDdepletion column (Miltenyi). The column efflu-
ent and collection of 2 consecutive washings with 1mL
of depletion buffer were combined and designated as
the CD1342 T cell fraction. T cell populations desig-
nated as ‘‘Before CD134 depletion’’ underwent CD11c
depletion alone to remove stimulator cells. Isolated
cell populations were rested for 24 hours in MLR me-
dium at 37C and subsequently, CD31 cells were fur-
ther purified by negative selection, using Pan T cell
Isolation Kit II (Miltenyi) and were used as responders
in secondaryMLR. CD32 cells (negatively isolated us-
ing CD31MicroBeads, Miltenyi) from original stimu-
lators or from an unrelated third-party donor were
irradiated (3300 cGy) and used as stimulators in sec-
ondary MLR. Responder and stimulator cells were
cultured in a 1:1 ratio (100 mL of 0.5  106 cells/mL)
in 96-well round-bottom microtiter plates in 4-6 rep-
licates. Cultures were continued for 6 days and 3H-
thymidine incorporation was assessed for the last 18
hours.
Limiting Dilution Assay for Cytotoxic
T-LymphocytePrecursor (CTLp)and IL-2-Producing
HTLp Frequencies
CTLp and HTLp frequencies were detected by
limiting dilution assay following previous protocols
[16,44], with some modifications. Briefly, respondersin serial 2-fold dilutions from 4  104 to 0.3125 
103 in 50 mL ofMLRmedia were plated in 24 replicate
wells of U-bottom 96-well microtiter plates. Irradiated
stimulator PBMC (5  104 cells in 50 mL) were added
to each well. After 72 hours of incubation at 37C in
5% CO2, 50 mL of supernatant were transferred to
96-well flat-bottom microtiter plates. For analysis of
HTLp frequency, 103 CTLL-2 cells/well were added
to the collected supernatants, incubation was contin-
ued for 8 hours, 3H-thymidine was added (1 mCi/well),
and 3H-thymidine incorporation by CTLL-2 cells was
measured after an additional 16 hours of culture. The
original plates, were used for assessment of cytolytic
CTLp frequency. IL-15 (final concentration 5 U/mL)
was added on days 3 and 6 to support cell viability,
and after completion of a total of 10 days of incubation,
4  103 51Cr-labeled target cells (PHA blasts) were
added to each well, incubation was continued for 4
hours and 51Cr release in the supernatant wasmeasured
with a gamma counter. For both CTLp and HTLp
frequency assays positive wells were defined as those
producing cpm greater than 3 standard deviations
above the mean of the 24 wells containing stimulators
alone (control). Frequencies were calculated using the
L-Calc Limiting Dilution Analysis Software (Stemsoft
Software Inc., British Columbia, Canada).
ELISpot Assay
IFN-g ELISpot assay kits (BD Bioscience) were
used to determine the frequency of CMV-specific T
cells prior to and after depletion of CD1341 alloreac-
tive cells. ELISpot plates were prepared and processed
according to the manufacturer’s instructions; 100 mL
of 0.5-1  106/mL irradiated (33 Gy) autologous
CD32 cells, used as APC, were seeded into each well
and were incubated for 2 hours with 1 mLCMV immu-
nogen (cell lysate of CMV-infectedCHO cells) or with
control (cell lysate of noninfected cell lysate) provided
by the manufacturer (MicroBix Biosystem Inc., Tor-
onto, Canada). Subsequently, 100 mL of 0.5-1  106/
mL CD31 responder cells were added per well and
were incubated for 20 hours at 37C. PHA (1 mg/
mL) was used as a positive control. The numbers of
spots were counted using ImmunoSpot S4 Pro Ana-
lyzer (Cellular Technology Ltd, Cleaveland, OH)
and the means of triplicate wells for each culture con-
dition were calculated. To determine the effect of
CD134-based allodepletion on helper and effector
CD41T cells after in vitro priming as described above,
CD1341 and CD1342 T cell fractions were isolated,
rested in media for 24 hours, and subsequently, 5 
104 CD41 cells from each fraction were challenged
with the same number of CD32 cells from the original
stimulators, in 100 mL of complete medium. Produc-
tion of IFN-g and IL-2 were determined by ELISpot
as described above.
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For immunophenotyping, the following mAbs
were used: anti-CD4-FITC, CD83-FITC, CD134-
PE, CD137-PE CD25-PE, CD11c-PE, CD71-PE,
CD69-PE, CD80-PE, CD3-APC, CD14-APC, and
HLA DR-APC (all from BD/Pharmingen, Toryanna,
CA). Isotype-matched antibodies were used as nega-
tive controls. Propidium iodide (PI) was used to gate
out dead cells. Intracellular Foxp-3 staining for Treg
cells was performed using the Human Regulatory T
Cell Staining kit (eBioscience) according to standard
protocol. Samples were analyzed in a Becton Dickin-
son FACScalibur (San Jose, CA), and at least 5000 pos-
itive events were measured for each sample.
Carboxyfluorescein Diacetate Succinimidyl Ester
(CFSE) Labeling and Analysis
CFSE labeling was done according to standard
protocol. Briefly, cells were washed once with PBS
and resuspended in 1 mL PBS (50  106). CFDA-SE
(Molecular Probes, Eugene, OR) was diluted in PBS
to a final concentration of 1 mM. Diluted CFDA-SE
(1 mL) was added to the cell suspension and incubated
at room temperature for 5 minutes. The labeled cells
were washed 3 times with MLR medium before use
in MLR cultures. Assessment of dividing cells was
done by flow cytometry and analysis with FlowJo
software.
HLA-Pentamer Analysis
PBMC fromHLA-A*0201 andCMVpositive indi-
viduals were stained with APC-labeled HLA-A*0201/
CMV-pp65 pentamer (NLVPMVATV; ProImmune,
Oxford, UK) for 10 minutes at room temperature.
The cells were washed twice and then stained with
anti-CD8-FITC (ProImmune) and anti-CD19-PE
(BD) mAbs. For detection of Wilms’ tumor (WT1)-
specific cells, we employed HLA-A*0201/WT1 pen-
tamer (RMFPNAPYL; ProImmune). WT1 peptide
(RMFPNAPYL) was synthesized at the Peptide/Pro-
tein Core Facility of Massachusetts General Hospital
and the purity was verified by HPLC. Autologous DC
from HLA-A*0201 homozygous individuals were
loaded with WT1 peptide at a concentration of 50
mg/mL in serum-free medium for 3 hours and used to
expandWT1-specificTcells in vitro.WT1stimulation
was continued for 5-7 days before HLA-mismatched
DC were added and after 2 days of allostimulation
CD1341 cells were depleted as described above. Sam-
pleswere analyzed in a BectonDickinsonFACScalibur,
and combined gates were set on live lymphocytes and
CD192 cells to preclude nonspecific pentamer staining
onB cells. Approximately 1 x 106 cells within a lympho-
cyte gate were acquired for each sample.RESULTS
Cell Divisions Display Distinct Kinetics after
Stimulation with HLA-Mismatched PBMC versus
Dendritic Cells
Themost broadly used ex vivo approach for gener-
ation of alloreactive T cells for experimental and pre-
clinical studies has been the coculture of PBMC used
as responders with irradiated unrelated HLA mis-
matched PBMC used as stimulators in MLR culture.
This approach is also established as a conventional
way to assess donor/recipient compatibility for clinical
purposes [2]. Other groups have chosen to use EBV
transformed B cells [45] or activated T lymphocytes
as allostimulators [46], because of their ease of collec-
tion and expansion to large numbers. However, these
approaches may not accurately represent the in vivo
events related to the generation of GVHD after trans-
plant. Based on the clinical presentation ofGVHD and
the preferential organ involvement in this condition, it
is most likely that professional APC of the host tissue
trigger the responses of donor T cells transferred
with the graft, which encounter recipient’s alloanti-
gens for the first time [1]. Therefore, as a first step in
our studies we compared the capacity of professional
APC versus unfractionated PBMC to activate alloreac-
tive T cells.
Responder PBMC were labeled with CFSE, and
responses in allogeneic MLR cultures were assessed
by evaluation of cell divisions. Coculture with alloge-
neic PBMC as stimulators induced replication only
in a small fraction of responder cells (Supplemental
Figure 1A). In parallel, we generated dendritic cells
(DC) from the same stimulator PBMC (Supplemental
Figures 2 and 3). When these DC were used as stimu-
lators, they displayed a much more potent stimulatory
capacity than allogeneic PBMC (Supplemental
Figure 1B). Thus, consistent with multiple previous
observations about their superior antigen-presenting
function, DC represent a preferred simulator popula-
tion for ex vivo allostimulation for the purpose of allo-
depletion. For this reason, all subsequent experiments
were conducted using DC as allostimulators.
Expression of CD134 is Upregulated on T Cells
during Allogeneic MLR
We sought to identify inducible cell surface mole-
cules that would allow selective depletion of alloreac-
tive T cells from MLR cultures using DC as
allostimulators. We assessed expression of activation
markers previously established to identify alloreactive
T cells involved in the induction of GVHD including
CD25, CD69, CD71, and the TNF receptor super-
family members CD134 and CD137. As shown
in Figure 1A, expression of CD25 was induced by 24
hours of culture and gradually increased to a maximum
level of 83.4% by day 7. CD69 was upregulated by 24
522 X. Ge et al.Figure 1. Activation-induced cell surface marker expression on responder T cells during MLR using as stimulators HLA-mismatched DC. (A)
PBMC were stimulated with HLA-mismatched DC for the indicated time intervals. Expression of cell surface markers CD25, CD71, CD69,
CD134, and CD137 on CD31 cells was evaluated daily by flow cytometry. (B) Cells were stained with CD3-, CD4-, and CD134-specific
mAbs and expression of CD134 on CD4 and CD8 cells (gated on CD3 cells) at various time points was examined. Results were reproduced
in 5 different responder: stimulator pairs. Mean values and standard deviations of CD41CD1341 cells in these 5 pair cultures for days 1-7
were: 0.4 1 0.1, 3.1 1 1, 5.8 1 1.2, 14.2 1 2.8, 23.5 1 2.1, and 39.2 1 3.0.hours, and its expression remained stable throughout
the culture period examined. CD134 was induced by
24 hours, and was gradually upregulated to reach
a maximum level of approximately 40% by 7 days (Fig-
ure 1A and B). Interestingly, expression of CD137 was
also induced after culture, but with kinetics of expres-
sion very different from that of CD134. There was
only a minimum expression of CD137 on days 1 and
2; its expression was upregulated to the maximum level
of 9.9% by day 4 and subsequently declined to 6.8% by
day 7 of culture (Figure 1A). Interestingly, our studies
showed that CD134 was the only activation-induced
marker that displayed similar kinetics with CD25, al-
beit with lower magnitude of expression. Specifically,
both markers displayed a gradual increase until day 2
of culture, significant increase by day 4 of culture,
andmaximum response on day 7 (Figure 1A). Inmouse
experimental systems, it has been reported that CD134
andCD137 signals promote T cell survival and control
the size of memory T cell pool [47,48]. However, we
detected neither CD134 nor CD137 on human mem-
ory T cells isolated from peripheral blood prior to in
vitro culture (Supplemental Figure 4).Previous studies have shown that induction of
aGVHD and cGVHD closely correlates with expres-
sion of CD134 but not CD137 [28,29]. Moreover,
multiple in vivo studies have provided evidence that
CD137mediates an inhibitory effect to the immune re-
sponse including autoimmune responses and GVHD
[37,49-54]. Thus, CD137-based depletion of alloreac-
tive T cells would not be a preferred approach. There-
fore, we focused our studies on the potential utility of
CD134 as a marker for selective allodepletion.
Depletion of CD1341 Alloreactive T Cells Reduces
Alloreactivity Against Original But Not Against
Third-Party Allogeneic Stimulators
First, we examined the functional consequences of
CD1341 T cell depletion on alloreactive T cell re-
sponses. Because our goal is to employ this approach
of ex vivo priming culture and subsequent depletion
of alloreactive T cells for clinical purposes, we evalu-
ated the outcome of CD134-allodepletion after the
minimum ex vivo culture time required to allow T
cell priming andupregulation ofCD134on alloreactive
T cells. We cultured PBMC with DC allostimulators
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CD1341 T cells, and examined responsiveness of the
remaining CD134-allodepleted populations. Restimu-
lation of CD134-allodepleted populations with origi-
nal allostimulators resulted in a proliferation response
that was reduced by 60% (0.6 log) compared to re-
sponses of nondepleted populations (Figure 2A). Anal-
ysis of responsiveness against original stimulators using
2 more quantitative experimental approaches revealed
that CD134-allodepletion reduced HTLp frequencies
to approximately 1 in 500 x 103 (Figure 2B), a threshold
belowwhich clinicalGVHD is rare [55]. This approach
also reducedCTLp frequencies against original allosti-
mulators by 92% (Figure 2C).
A major issue related to alloreactive T cell deple-
tion is whether effector T cells with different antigenic
specificity are also nonspecifically depleted from the re-
maining T cell populations. To address this question,
CD134-allodepletedT cells were stimulated in parallel
with either original allostimulators or unrelated third-
party allostimulators, and responses were examined by
thymidine incorporation. In contrast to the reduced
responsiveness against original allostimulators, prolif-
eration against third-party allostimulators was not
affected, but reached levels comparable to those ob-
served without CD1341 T cell depletion (Figure 2A).
Depletion of CD1341 Alloreactive T Cells
Eliminates Allospecific Helper and Effector CD41
Cells But Preserves Effector CD81 T Cells
Expressing Perforin and Granzyme B
Our studies showed that depletion of CD1341 al-
loreactive T cells abrogated responses of alloantigen-
specific CD81T cells as determined by 92% reduction
of CTLp frequencies against original allostimulators
(Figure 2C). However, our detailed kinetics studies
revealed that at 48 hours of MLR, at which time we
did CD134-based allodepletion, CD134 was almost
exclusively expressed on CD41 cells (Figure 1B). In
contrast, its expression on CD81 T cells, as deter-
mined by gating onCD4-T cells, was almost undetect-
able. In fact, expression of CD134 on CD81 T cells
was much lower, and was observed only after pro-
longed periods of culture (Figure 1B). These observa-
tions suggest that after depletion of CD1341CD41
alloreactive T cells, CD81 T cells are retained within
the residual populations but are incapable of respond-
ing to original allostimulators, consistent with previ-
ous observations [56]. Therefore, we undertook
further studies to evaluate the effect of CD134-allode-
pletion on alloantigen-specific CD41T and on CD81
T effector cells.
We evaluated alloantigen-specific CD41 T helper
cell function by assessing IL-2 producers and CD41T
effector cell function by assessing IFN-g producers.
Before and after CD134-allodepletion, we cultured
CD41 T cells with irradiated original allostimulatorsand we assessed IL-2 and IFN-g-producing CD41
cells, by ELISpot. As shown in Figure 3A, CD134-
allodepletion eliminated both alloantigen-specific
IL-2 producing CD41 T helper cells and IFN-g-pro-
ducing CD41 T effector cells.
To determine the effect of CD134-allodepletion
on the expression of CD81 T effector cells, we exam-
ined perforin and granzyme B-expressing CD81 cells
in CD1341 and CD1342 populations after depletion.
The majority of perforin and granzyme-B-express-
ing CD81 cells were within the CD1341 popula-
tion (Figure 3B). However, a considerable proportion
of perforin-expressing and granzyme-B-express-
ing CD81 T effector cells was retained within the
CD1342 fraction (Figure 3B). Although one concern
might be that the maintenance of perforin and gran-
zyme-BexpressingTcells couldbe secondary to incom-
plete allodepletion of CD1341 cells, flow cytometry
studies determined that CD134-allodepletion resulted
in populations that were more than 97% CD1342
(data not shown).
Depletion of CD1341 Alloreactive T Cells Allows
Preservation of Virus-Specific and Leukemia-
Specific Effectors
Next, we examined whether effector CD81T cells
with clinically important antigen-specific functions
were retained in CD134-allodepleted populations.
Morbidity and mortality related to opportunistic in-
fections is a serious risk of allogeneic transplantation.
Common opportunistic infections related to impaired
T cell immunity in a transplantation setting are re-
lated to reactivation of latent viruses CMV, varicella
zoster virus (VZV), and EBV. Among them, CMV is
a major source of posttransplant morbidity because
of the high prevalence of infection among healthy
populations, leading to frequent reactivation in the
posttransplant period. To detect pathogen-specific
cells within the CD81 T cell population, we used
fluorescent-labeled pentamer of the HLA-A*0201 al-
lele specific for the immunodominant CMV epitope
NLVPMVATV. Using PBMC from responders who
where homozygous for HLA-A*0201 and positive
for CMV, we observed that CD134-allodepletion
did not eliminate CMV-specific effectors. In fact,
there was rather a small but reproducible increase in
the proportion of CMV-specific T cells within the en-
tire CD81 T cell population after depletion of
CD1341 alloreactive T cells (Figure 4A). To further
assess the functional status of such CMV-specific
cells, we analyzed their effector function by evaluating
their capacity to produce IFN-g in response to stimu-
lation with CMV immunogen. Alloantigen-primed
PBMC populations, before and after CD134-allode-
pletion, were incubated with CMV pathogens, and
responses were examined by ELISpot specific for
IFN-g. Functional responses of CMV-specific,
524 X. Ge et al.IFN-g- producing T effector cells were comparable
prior to and after depletion of CD1341 alloreactive
T cells (Figure 4B). Thus, depletion of CD1341 allor-
eactive T cells allowed preservation of CMV-specific
effector CD81 cells that were capable of exhibiting
functional responses.
To determine whether our approach of CD134-
based allodepletion might compromise leukemia-
specific immunity, we assessed responses specific to
Wilms’ tumor (WT1) protein, a previously established
surrogatemarker for leukemia-specific responses. Anti-
gens derived from the WT1 protein are overexpressed
in acute and chronic myelogenous leukemias. Interest-
ingly, 4 HLA-A*0201-restricted WT1-derived epi-
topes display natural immunogenicity not only in
patients with hematologic malignancies but also in
healthy donors [57]. To determine whether CD134-
based allodepletion might compromise leukemia-
specific immunity we assessedWT1-specific responses
prior to and after depletion of CD1341 alloreactive T
cells, using PBMC from HLA-A*0201 homozygous
individuals as responders. To induce expansion of
WT1-specific cells to levels that allowed their reliable
detection with APC-labeled WT1 peptide-HLA-
A*0201 pentamer, first we cultured PBMCwith autolo-
gous DC loaded with WT1 peptide (RMFPNAPYL).
Subsequently, allostimulation was conducted with
allogeneic DC in MLR cultures followed by depletion
of alloreactive CD1341 T cells on day 2 of MLR, as
described above. Low levels of WT1-specific CD81
T cells were detected in PBMC and were increased by
priming with WT1-bearing autologous DC (Table 1).
Following allostimulation, the fraction of WT1-spe-
cific cells within the entire CD81 T cell population
was reduced indicating thatCD81Tcellswith different
specificities were expanding. Importantly, CD134-allo-
depletion permitted retention ofWT1-specific CD8T
cells in the allodepleted populations (Table 1).
Depletion of CD1341 Alloreactive T Cells Allows
Preservation of Treg Cells
In vitro studies have determined that depletion of
CD251 alloreactive T cells abrogates specific alloreac-
tivity in vitro [22,58]. However, clinical trials using
CD25-depleted allografts have revealed that residual
GVHD remains a problem [26,27,59]. Because CD25
is expressed not only on activated effectors but also
on Treg, an alloantigen-primed T cell inoculum de-
prived of Treg may promote GVHD even after allode-
pletion because of the elimination of the natural
suppressive function of Treg. Therefore, we compared
the effect of CD25-based and CD134-based allodeple-
tion on the expression of Treg in the remaining T cell
populations. As shown in Figure 5, CD25-based deple-
tion resulted in a significant reduction of Foxp31Treg
cells from the allodepleted T cell populations. In con-
trast, Treg were retained after CD134-allodepletion.
DISCUSSION
Here, we described a rapid and efficient approach





























































Figure 2.Depletion of CD1341 alloreactive T cells reduces alloreactivity against original but not against third-party allostimulators. (A) PBMC
were cultured with mismatched DC for 2 days, CD1341 T cells were depleted from alloreactive responders using LD depletion columns (Mil-
tenyi), and the remaining populations were rechallenged with T cell depleted PBMC from the original allostimulators or from third-party allos-
timulators. Responses were assessed by thymidine incorporation. Results were reproduced in 3 different responder: stimulator pairs. (B-C) In the
same populations of alloreactive responders, frequency of HTLp, and frequency of CTLp against original stimulators were examined before and
after depletion of CD1341 alloreactive T cells. Results were reproduced in 3 different responder: stimulator pairs.
Selective Allodepletion by Targeting CD1341 T Cells 525responder cells with DC allostimulators for 48 hours.
Findings with potentially major clinical significance
by using this approach are the observations that
CD134-allodepeletion reduced alloantigen-specific
HTLp and CTLp frequencies but maintained re-
sponses to third-party alloantigen, CMV pathogen,
and WT1 leukemia antigen. The use of patient-
derived DC as allostimulators for allodepletion for
clinical purposes will provide the advantage that only
very low numbers of patients’ PBMC are required,
which can be efficiently differentiated intoDC in vitro.
Subsequently, these DC are capable of engaging and
activating a large number of responder donor T cells
during ex vivo allostimulation. Furthermore, the 48-
hour requirement for allostimulation reduces the
need for prolonged ex vivo manipulation of the cell
inoculum. Although in the present study we used
MHC-disparate responder stimulator pairs, it will be
important to evaluate the applicability of this approach
in a matched, haploidentical or single HLA-mis-
matched transplantation setting in which selective
allodepletion after ex vivo priming is a previously
established way to reduce alloreactivity [45,56].
There is evidence that expression of CD134 is in-
duced on peripheral CD41 and CD81 T cells of pa-
tients undergoing allogeneic SCT, and strongly
correlates with aGVHD and cGVHD [28,31]. In those
studies, expression of CD1341 on CD41 and CD81
cells correlated best with aGVHD activity during ther-
apy and was a better marker than CD25, CD69, and
HLA-DR in predicting disease activity. Interestingly,
expression of CD25, CD69, andHLA-DRwere hardly
expressed on CD1341CD31 T cells, indicating that
these CD1341CD31 T cells do not necessarily
Figure 3. Depletion of alloreactive CD1341 cells eliminates allospecific helper and effector CD41 T cells but preserves effector CD81 T cells
expressing perforin and granzyme B. (A) PBMC were stimulated with mismatched DC for 2 days, CD1341 and CD1342 T cell fractions were
isolated, rested in media for 24 hours, and subsequently, CD41 cells from each fraction were challenged with APC from the original stimulators.
Production of IFN-g and IL-2 were detected by ELISpot assay. (B) PBMCwere stimulated with mismatched DC for various time intervals (2-7
days) and subsequently CD1341 and CD1342T cell fractions were isolated. Recovered cells were stained with APC-conjugated anti-CD8mAb
and with either FITC-conjugated antiperforin mAb or FITC-conjugated granzyme-B mAb and analyzed by flow cytometry. A representative
result from 3-day cultured cells is shown. Results were repeated in 4 different responder:stimulator pairs. Gray shaded histograms represent stain-
ing with the appropriate isotype matched control (IgG2b for perforin and IgG1 for granzyme B).
526 X. Ge et al.represent a recently activated T cell population. These
CD1341CD252CD692HLA2DR2 cell populations
may be important mediators of GVHD and would es-
cape CD25-allodepletion, possibly explaining the re-
sidual GVHD observed in patients treated with this
approach. CD1341CD81 cells have been detected in
all patients with cGVHD [31]. Further supporting
and extending these findings regarding the involve-
ment of CD134(OX40) in GVHD, it was reported
that CD1341 T cells were present in almost all skin
specimens of patients with aGVHD and cGVHD
[29]. OX40L1 cells were present in the skin specimens
of 6 of 11 patients with aGVHD and of 14 of 15 pa-
tients with cGVHD. Interestingly, the vast majority
of OX40L1 cells displayed reactivity with mast cell-
specific antitryptase antibody, indicating that OX40L
positive mast cells were involved in mediating skin-
specific GVHD via CD134(OX40):OX40L interac-
tions.
Based on previous reports indicating that CD134 is
predominantly expressed on effector T cells [30,39],
we sought to determine the consequences of
CD1341 T cell depletion from allo-activated T cell
populations. Our observations were consistent with
those previous studies as they revealed that expression
of CD134 was induced on both CD41 and CD81 T
cells during their culture withmismatched stimulators.
However, depleting CD1341 cells following a time in-
terval of culture that induced minimal expression of
CD134 on CD8T cells, resulted in a T cell population
that had dramatically reduced specific alloreactivity
but preserved pathogen-specific and leukemia-specific
Figure 4.Depletion of CD1341 alloreactive T cells allows preservation of antiviral responses. (A) PBMCwere stimulated with mismatched DC
for 2 days and were subsequently depleted from CD1341T cells. Nonactivated (NA) PBMC, primed cells before CD1341T cell depletion (Be-
fore) and after CD1341 T cell depletion (After), were stained with CD8-FITC mAb, CD19-PE mAb, and APC-labeled HLA-A*0201/CMV-
pp65 pentamer (NLVPMVATV), and analyzed by flow cytometry. Cells were gated on CD192 lymphocytes. Results from 2 different responder:
stimulator pairs are shown (top and bottom panels). (B) Purified, alloantigen-primed CD31 cells before or after depletion of CD1341 T cells
were plated in triplicates in the presence of autologous APC loaded with CMV immunogen (cell lysate of CMV-infected CHO cells) or with
control (cell lysate of noninfected cell lysate). The means of triplicate wells were obtained, and results are shown as ratios of spots generated
in the presence of antigen over those obtained in negative control triplicates. Results are representative of those obtained from 3 different re-
sponder:stimulator pairs.
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effector T cells and reduced the HTLp frequencies
against original allostimulators to levels of 1:500 
103 cells, which is predictive of grade 0-I GVHD
that is clinically insignificant [55]. Taken together,
these observations indicate that CD134-based allode-
petetion may specifically eliminate alloreactive effec-
tor T cells, including those that do not express
CD25 or CD69, while at the same time preserves path-
ogen-specific and leukemia-specific effectors.
Our present studies showed that CD134-allode-
pletion preserved Foxp31 Treg cells, consistent with
previous observations that CD134 is expressed on
only a fraction of the Treg cells [60]. This issue is of
critical importance, especially in light of the observa-
tion that patients transplanted with CD25-allode-
pleted grafts do develop residual GVHD, suggesting
that loss of Treg by that approach might account for
this outcome. Recently, it was reported that after
CD25-allodepletion, Foxp31 cells can expand in the
allodepleted product and may be derived from the
CD252 Treg fraction escaping CD25-allodepletion
[61]. However, several issues related to the significance
of this finding involve the low proportion of CD252
Treg that mainly belong to the adaptive Treg popula-
tion, and the distinct biologic function of this Treg
subset [62]. Importantly, the severity of GVHD in pa-
tients receiving CD25-allodepleted grafts inversely
correlated with the levels of CD251 Treg but not
with CD252Treg in their donors [61]. Thus, until fur-
ther clinical studies are completed, approaches that re-
tain natural Treg in the allodepleted grafts such as we
have shown here would be highly desirable.
Previous work has shown not only that CD134 is
expressed on activated T cells but also that ligation
of CD134 on T cells leads to their further differentia-
tion into effectors [30,63]. Ligation of CD134 in vivo
by an agonist anti-CD134 antibody induced activation
of CD41 T cells, accumulation of differentiated effec-
tors and killed host animals receiving allogeneic grafts,
because of GVHD [30]. Interestingly, in that system,












Donor 1 0.11 0.71 0.22 0.16
Donor 2 0.02 0.85 0.38 0.37
PBMC from HLA-A*0201-positive individuals were used either
prior to any treatment or after incubation with autologous DC
loaded with WT1 peptide (RMFPNAPYL) for 7 days. Subse-
quently, cells were cocultured with allogeneic HLA mismatched
DC for 2 days and were depleted of CD1341 alloreactive T
cells. Detection of WT1-specific cells was done by staining with
APC-labeled HLA-A*0201/WT1 pentamer.
Figure 5. Depletion of CD1341 alloreactive T cells allows preservation of Treg cells. Nonactivated PBMC (NA), and PBMC populations
primed with mismatched DC for 2 days were depleted either of CD251 alloreactive T cells or CD1341 alloreactive T cells, and were stained
with anti-CD4-FITC, anti-CD25-PE, and anti-FoxP-3-APCmAb using the Human Regulatory T Cell Staining kit (eBioscience) and analyzed
by flow cytometry. Results were reproduced in 2 separate experiments for both CD25-based and CD134-based depletion.
528 X. Ge et al.accumulation of effectors was not only because of ex-
pansion of CD1341 T cells but also because of activa-
tion and expansion of CD1342 T cells, which were
activated by APC that were induced to express costi-
mulatory molecules and cytokines after interaction
with CD1341 T cells [30]. Thus, as established by
our present data, depletion of cells rendered CD1341
during allogeneic MLR may prevent activation of ef-
fectors with different antigenic specificities that remain
CD1342 during culture, but could be activated
through APC receiving signals from CD1341 T cells.
This fact could explain our findings that CD134-allo-
depleted T cell populations retained pathogen-specific
and leukemia-specific effectors.
In conclusion, our present data suggest that the use
of CD134-allodepleted allografts may improve alloge-
neic SCTby reducingGvHDwithout loss of pathogen-
specific and leukemia-specific immunity, as determined
by maintenance of CMV-specific and WT1-specific
CD81 T cells.
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